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Abstract
Hemorrhagic shock (HS) is associated with high mortality. A severe decrease in blood pressure causes the intestine, a major
site of digestive enzymes, to become permeable – possibly releasing those enzymes into the circulation and peritoneal
space, where they may in turn activate other enzymes, e.g. matrix metalloproteinases (MMPs). If uncontrolled, these
enzymes may result in pathophysiologic cleavage of receptors or plasma proteins. Our first objective was to determine, in
compartments outside of the intestine (plasma, peritoneal fluid, brain, heart, liver, and lung) protease activities and select
protease concentrations after hemorrhagic shock (2 hours ischemia, 2 hours reperfusion). Our second objective was to
determine whether inhibition of proteases in the intestinal lumen with a serine protease inhibitor (ANGD), a process that
improves survival after shock in rats, reduces the protease activities distant from the intestine. To determine the protease
activity, plasma and peritoneal fluid were incubated with small peptide substrates for trypsin-, chymotrypsin-, and elastase-
like activities or with casein, a substrate cleaved by multiple proteases. Gelatinase activities were determined by gelatin gel
zymography and a specific MMP-9 substrate. Immunoblotting was used to confirm elevated pancreatic trypsin in plasma,
peritoneal fluid, and lung and MMP-9 concentrations in all samples after hemorrhagic shock. Caseinolytic, trypsin-,
chymotrypsin-, elastase-like, and MMP-9 activities were all significantly (p,0.05) upregulated after hemorrhagic shock
regardless of enteral pretreatment with ANGD. Pancreatic trypsin was detected by immunoblot in the plasma, peritoneal
space, and lungs after hemorrhagic shock. MMP-9 concentrations and activities were significantly upregulated after
hemorrhagic shock in plasma, peritoneal fluid, heart, liver, and lung. These results indicate that protease activities, including
that of trypsin, increase in sites distant from the intestine after hemorrhagic shock. Proteases, including pancreatic
proteases, may be shock mediators and potential targets for therapy in shock.
Citation: Altshuler AE, Penn AH, Yang JA, Kim G-R, Schmid-Scho ¨nbein GW (2012) Protease Activity Increases in Plasma, Peritoneal Fluid, and Vital Organs after
Hemorrhagic Shock in Rats. PLoS ONE 7(3): e32672. doi:10.1371/journal.pone.0032672
Editor: Jo ¨rn Karhausen, Duke University Medical Center, United States of America
Received December 1, 2011; Accepted February 2, 2012; Published March 27, 2012
Copyright:  2012 Altshuler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health (NIH) GM-85072. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: Dr. Schmid-Schonbein is a scientific consultant for InflammaGen Therapeutics Inc. and owns stock. InflammaGen Therapeutics has
interest in treatment of multiple organ failure. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: aaltshul@ucsd.edu
. These authors contributed equally to this work.
Introduction
Trauma is associated with high mortality [1]. One major cause
of death in trauma patients is hemorrhagic shock (HS) [2], during
which the intestine is underperfused [3]. As a result of ischemia,
intestinal permeability increases [4], allowing luminal content
including pancreatic digestive enzymes, to escape from the lumen
into the wall of the intestine [5,6]. Proteases that have penetrated
the barrier can further increase the overall proteolytic activity in
the intestinal wall by activating MMPs [6,7]. Pretreatment in the
intestinal lumen with a broad spectrum serine protease and lipase
inhibitor (nafamostat mesilate, ANGD), reduces circulating
neutrophil activation [8] and delays or prevents mortality in
experimental shock models indicating the intestine as a key organ
to preserve during shock [9–10]. One of the possible effects of
ANGD in the lumen of the intestine could be to prevent active
pancreatic proteases from entering the circulation, by helping to
preserve the mucosal barrier and/or by inhibiting proteases that
enter the intestinal wall.
Shock mediators entering or formed in the wall of the intestine
may be transported out of the intestine via the portal venous
system, the intestinal lymph, or by passive transport through the
intestinal wall into the peritoneum [11,12]. It is unknown whether
digestive enzymes are among the mediators transported out of the
intestine into the systemic circulation and other organs during
hemorrhagic shock. Should this occur, uncontrolled proteolytic
activity in compartments outside the lumen of the intestine could
lead to cleavage of important plasma proteins and/or cell surface
receptors contributing to the morbidity and possible mortality of
the animal [13]. In pancreatitis, which has similarities to shock and
may also result in multi-organ failure, plasma trypsin levels have
been correlated with mortality [14]. In shock, pancreatic amylase
and lipase have been measured in plasma and predict mortality
[15], but the presence and activity of pancreatic proteases remains to
be determined.
It has been hypothesized that, if released into the systemic
circulation, pancreatic proteases will not be active due to binding
to plasma protease inhibitors (serpins; e.g. a2-macroglobulin, a1-
antitrypsin, etc.) [16]. However, the blocking ability of serpins is
limited. They may be saturated, and it has been shown that while
binding to these inhibitors prevents proteases like trypsin from
digesting large proteins, smaller peptides are still cleavable [17].
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risk for proteolytic degradation [13].
Because of possible binding to vascular antiproteases, measure-
ments of the potential for proteolysis in shock plasma may be
negatively skewed if the selected test substrate is a large globular
protein such as casein, a substrate commonly used to measure
non-specific protease activity. Additionally, we have observed that
serine protease activity in plasma samples will decrease with
increasing storage time (220uC) and/or freeze-thaw cycles,
further increasing the difficulty of obtaining a complete spectrum
of the proteolytic potential in shock plasma [18]. Therefore, we
recognized a need to measure small peptide proteolytic activity on
fresh samples after hemorrhagic shock.
The objectives of this study were to determine in experimental
hemorrhagic shock (1) select protease activities and concentrations
outside of the intestine (plasma, peritoneal fluid, vital organs) by
plate zymography, gel zymography, and immunoblotting and (2)
whether the mechanism by which serine protease inhibition in the
intestinal lumen provides protection in hemorrhagic shock is due
to reduction of protease activity in the systemic circulation. Our
results indicate that protease activity and levels are elevated after
hemorrhagic shock. While ANGD treatment reduces neutrophil
infiltration into organs distant from the intestine, it does not reduce
protease activity in the tissues tested at 2 hours after hypotension.
Methods
Animal Protocol and Tissue Collection
The animal protocols were reviewed and approved by the
University of California, San Diego Animal Subjects committee
(Protocol Number S01113). Male Wistar rats (body weight
between 270 and 460 g; 347649 g [mean6sd], Harlan, India-
napolis, IN) were administered general anesthesia (xylazine,
20 mg/kg i.m., followed 20 minutes later by sodium pentobarbi-
tal, 50 mg/kg i.m.). After laparotomy, 2 ml saline were injected
into the peritoneal space then drained after 2 minutes. The lavage
fluid was collected in a tube containing 20 ml heparin and
centrifuged (1000 g, 5 min) to remove any accumulated cells.
Next, the left femoral vein and artery were cannulated. We then
injected either saline (HS+SAL group) or a serine protease inhibitor
(6-amidino-2-naphtyl p-guanidinobenzoate dimethanesulfate,
ANGD, nafamostat mesilate, Torii Pharmaceutical, Chiba, Japan;
HS+ANGD group; 2 mg/ml ANGD in 100 mg/ml D-glucose in
saline) into the lumen of the small intestine (7–10 ml at two to
three injection sites to fill the small intestine but avoid
circumferential stretching). To prevent clotting in catheters and
shed blood, animals were heparinized (10 U/ml i.v., assuming 6%
blood volume per body weight) prior to inducing hemorrhagic
shock.
Mean arterial blood pressure (MAP) was reduced to 35 mmHg
by withdrawing blood through the venous catheter (0.2 ml/min).
This pressure was maintained by further withdrawal/return of
blood over a 2-hour ischemic period. The first two milliliters of
shed blood were collected, centrifuged (1000 g, 5 min), and stored
at 4uC as pre-hemorrhagic shock (Pre-HS) plasma. After 2 hours,
the remaining shed blood plus 2 ml of heparinized saline (to
replace the 2 ml of pre-ischemic blood) was reinfused (0.5 ml/min
i.v.), and the animal observed for 2 hours. At the end of this
reperfusion period, 4 ml of post-hemorrhagic shock (Post-HS)
blood was collected, centrifuged (1000 g, 5 min) and plasma
aliquots were either immediately measured for protease activity or
frozen (220uC). An aliquot of post-HS plasma received an extra
10 U/ml heparin before centrifugation. Post-peritoneal lavage
fluid was collected in the same manner as described above. The
brain, heart, liver, and lung were collected immediately after
euthanasia (120 mg/kg sodium pentobarbital i.v.) and snap frozen
for later protease assays, gelatin zymography, and immunoblot
analysis. Separate animals (No-HS group) were euthanized
immediately after femoral catheterization for control brain, heart,
liver, and lung tissue samples. Given the limited availability of Pre-
HS plasma, some assays were performed using remaining
unpaired Pre-HS plasma (i.e. Pre-HS plasma drawn from animals
in both the HS+SAL and HS+ANGD groups).
Brain, heart, liver, and lung were homogenized (0.1 g tissue/ml)
in phosphate buffered saline (PBS) (pH 6) containing 0.5%
hexadecyltrimethyl bromide (HTAB) for myeloperoxidase (MPO)
assays, MMP-1/9 assays, and gelatin gel zymography. Tissues were
homogenized for immunoblot analysis in CelLytic buffer (Sigma-
Aldrich, St. Louis, MO) with protease inhibitor cocktail (Sigma-
Aldrich). Homogenates were centrifuged (1.4610
4 g, 4uC, 30 min)
and the supernatants collected, aliquoted, and stored at 280uC.
After removal from 280uC, protein concentrations were measured
(BCA protein assay kit, ThermoScientific, Waltham, MA) prior to
use of samples in subsequent experiments.
Microplate Assays
All microplate assays were performed in triplicate in 96 well
black-sided flat bottom polystyrene plates (Corning, New York,
NY) using a microplate reader (FilterMax F-5 Multi-mode,
Molecular Devices, Sunnyvale, CA).
Since shed blood was held outside the body for 2 hours during
the ischemic period, we performed a pilot study to confirm that
any increased protease activity after reperfusion was not due to
increases in-vitro in the shed whole blood. We compared freshly
drawn blood to blood that had been stored for 2 hours for all
protease activity measurements. No differences were detected.
Myeloperoxidase (MPO) Activity Assay. As a measure
of the degree of inflammation after shock, we measured
myeloperoxidase activity for neutrophil infiltration/accumulation
in lung, liver, heart, and brain. 20 ml of 1 mg/ml brain, heart,
liver, or lung homogenate, were added to 180 ml of 0.167 mg/ml
o-dianisidine dihydrochloride (Sigma-Aldrich) and 0.005% H2O2
in PBS (pH 6). We measured absorbance at 450 nm every
5 minutes for 1 hour at 37uC. MPO activity is presented as the
change in absorbance per minute per milligram of protein.
Trypsin-, Chymotrypsin-, and Elastase-like Activity
Measurements. The ability of shock plasma and peritoneal
lavage fluid to digest small peptides was determined using
benzoylarginyl-p-nitroanilide hydrochloride (BAPNA, Sigma-
Aldrich), N-succinyl-L-phenylalanine-p-nitroanilide (SPNA, Sigma-
Aldrich), N-succinyl-alanine-alanine-proline-leucine-p-nitroanilide;
L-leucinamide, N-(3-carboxy-1-oxopropyl)-L-alanyl-L-alanyl-L-prolyl-
N-(4-nitrophenyl) (SAAPLPNA, Sigma-Aldrich), which are substrates
for trypsin-like, chymotrypsin-like, and elastase-like enzyme activity,
respectively. Stock solutions were prepared in dimethylsulfoxide
(DMSO) (BAPNA-20 mM, SPNA-100 mM, and SAAPLPNA-
84.7 mM). Stock solutions were then diluted in PBS to their working
solution concentrations (0.5 mM for BAPNA, 5 mM for SPNA, and
0.5 mM for SAAPLPNA). 20 ml of fresh plasma, peritoneal fluid, or
PBS as control were added to either 180 mlo fP B S( c o n t a i n i n gt h e
same percentage of DMSO as substrates) for control or working
solution of BAPNA, SPNA, or SAAPLPNA, respectively. Light
absorbance readings (at 405 nm) were made at time=0 hr and 24 hrs
(resulting measurements were well below the maximum absorbance for
each substrate). Post hemorrhagic shock plasma samples were
susceptible to light diffraction due to colloid material (opacity) if
allowed to evaporate. Therefore, plates were kept covered at room
temperature. Opacity was also minimized if post shock blood had been
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opacity in the samples. A normalized absorbance was computed as:
An=DASa+Sub2DASa2DASub where DASa+Sub is the change in
absorbance of the sample+substrate, DASa is the change in
absorbance of the sample+PBS w/ DMSO, and DASub is the
change in absorbance of the substrate+PBS.
To convert trypsin-, chymotrypsin-, and elastase-like activities
into equivalent uninhibited concentrations of each enzyme,
purified bovine trypsin (Sigma-Aldrich), chymotrypsin (Sigma-
Aldrich), and elastase (Worthington Biochemical Corporation,
Lakewood, NJ) were serially diluted (micromolar to femtomolar
range) and added to their respective substrates. The plates were
read at 24 hours and a calibration curve generated to estimate the
equivalent uninhibited concentration, based on proteolytic
activity, in the samples. 24 hours of incubation was necessary to
achieve adequate signal to noise ratios with these substrates even
when using pure enzymes.
Casein Protease Activity Assay. To assess the ability of
proteases in plasma and peritoneal lavage fluid to digest large
globular proteins, we utilized the Enzchek protease assay kit
(Invitrogen, Carlsbad, CA), which consists of casein internally
quenched with Texas Red fluorophores (Ex/Em: 589/617 nm)
reconstituted in a digestion buffer. One part fresh plasma or
peritoneal fluid was added to four parts digestion buffer and five
parts casein substrate (FSample+Casein). To determine how much of
the measured activity was due to serine proteases, a second
aliquot of each sample received 1 mM (final concentration)
phenylmethylsulfonyl fluoride (PMSF), a serine protease
inhibitor. To correct for absorption or auto-fluorescence of the
sample at 617 nm, we mixed a known quantity of Texas Red
(Vector Laboratories, Burlingame, CA) in digestion buffer 9:1 with
sample (FTx+Sample) or digestion buffer (FTx+Buffer). Samples were
incubated for 100 min at 37uC in a microcentrifuge tube before
pipetting the reaction mixture to the microplate and reading
fluorescence. Caseinolytic activity (Relative Fluorescent Units;
RFU) was determined as: (FTx+Buffer/FTx+Sample)*(FSample+Casein).
MMP-1/9 Activity Measurements. Pilot studies revealed
that, unlike other activities we examined, MMP-1/9 activity was
not diminished by storage at 220uC, which permitted the use of
stored plasma and peritoneal fluid. Plasma (100-fold final dilution)
or peritoneal fluid (50-fold final dilution) samples were loaded into
a 96 well plate with fluorescent MMP-1/9 substrate (American
Peptide Company, Sunnyvale, CA) diluted to a final concentration
of 10 mM in digestion buffer (100 mmol NaCl, 23 mmol Tris HCl,
2.4 mmol CaCl2,5mM ZnCl2, 0.01% Brj 35, pH 7.6, with 1 mM
PMSF to inhibit any residual serine protease activity). Samples
with digestion buffer only (no substrate) served as control for
autofluorescence. Sample fluorescence was measured every
5 minutes for 30 minutes (Ex/Em: 365/450 nm). Activity was
reported as the initial change of substrate fluorescence per unit
time (relative fluorescent units per minute).
Gelatin Zymography
As a first step towards identification, we employed gelatin gel
zymography to determine molecular weights of prominent
proteases appearing in tissue homogenates, stored plasma, and
stored peritoneal fluid after hemorrhagic shock. It should be noted
that gel zymography characteristically separates all proteases from
non-covalently bound inhibitors (pilot studies revealed this
includes the binding of ANGD to trypsin, chymotrypsin, or
elastase) and can also activate some pro-enzymes to become
capable of cleaving the gelatin substrate.
For tissue homogenates, 30 mg of protein was added to equal
volume of Laemmli sample loading buffer (Bio-Rad, Hercules,
CA). Either 0.5 ml of plasma or 2 ml of peritoneal fluid were
diluted in 8 ml sample loading buffer before loading the gel.
Samples were separated by gel electrophoresis on a 4% stacking
gel and 10% SDS-PAGE resolving gel containing 80 mg/ml
porcine gelatin (Sigma-Aldrich) as the protease substrate. After
protein separation, proteins in the gels were renatured in four 15-
minute washes of 2.5% Triton X-100 solution. Gels were
incubated overnight at 37uC in developing buffer (0.05 M Tris
base, 0.2 M NaCl, 4 mM ZnCl2, 5 mM CaCl2?2H2O). Following
incubation, gels were stained (50% methanol, 10% acetic acid,
40% water, and 0.25% Coomassie blue solution) for three hours.
Gels were destained (50% methanol, 10% acetic acid, and 40%
water solution) until the first appearance of bands, then transferred
to water for rehydration before acquiring images.
To confirm the low molecular weight bands (20–30 kDa) were
serine proteases, gels were run in duplicate. One gel was renatured
as described above. The second gel was renatured and developed
in buffers containing 200 mg/ml of the serine protease inhibitor,
ANGD. Pilot studies with pure trypsin, chymotrypsin, or elastase,
with and without ANGD, confirmed that ANGD can inhibit each
enzyme as measured by plate zymography.
To determine trypsin-specific activity of lower bands, select gels
were also renatured and developed in 100 mM tosyl-lysine
chloromethyl ketone hydrochloride (TLCK) (Sigma-Aldrich), a
specific inhibitor of trypsin-like enzymes.
The gel analysis function in ImageJ (http://rsbweb.nih.gov/ij/)
was used to quantify protease activity bands by densitometry.
Values are reported in Relative Intensity Units (RIU).
Immunoblotting
Based on results from our lab suggesting that trypsin is better
able to penetrate into the wall of an ischemic intestine than
chymotrypsin or elastase [19], and on preliminary results from this
study suggesting MMP-9 activity is increased in HS, we focused
our immunoblot studies on those two proteases.
To determine the relative concentrations of MMP-9 and
pancreatic trypsin in plasma, peritoneal fluid, and tissue
homogenates, each fluid was first denatured by mixing 1:1 with
26sample loading buffer (Bio-Rad) containing the reducing agent
b-mercaptoethanol (0.05% by volume) before boiling for 10 min-
utes. 2 ml (MMP-9 assays) or 4 ml (trypsin assays) of denatured
plasma solution or 10 ml denatured peritoneal fluid solution was
loaded per well into an SDS-PAGE gel (8% resolving, 4% stacking
for MMP-9; 12% or precast 4–20% gels from Bio-Rad for trypsin).
For detection of MMP-9 and trypsin in tissue homogenates we
loaded 40 mg and 80 mg of protein per well, respectively. After
separation, proteins were transferred onto a nitrocellulose
membrane (Bio-Rad). Membranes were blocked with 5% bovine
serum albumin in tris-buffered saline with 0.5% Tween-20 (TBS-
T). Primary antibodies against MMP-9 (1:1000, ab-76003,
Abcam, Cambridge, MA), pancreatic trypsin (1:1000, sc-137077,
Santa Cruz Biotechnology, Santa Cruz, CA), GAPDH (1:2000; sc-
48167) and b-actin (1:2000, sc-130301, Santa Cruz Biotechnology)
were diluted in 1% BSA in TBS-T and incubated with membranes
overnight at 4uC on a rotary shaker (60 cycles/minute). Primary
antibodies were washed with TBS-T (36, 10 min) before
application of anti-goat, -rabbit, or -mouse secondary antibodies
(1:3000; Santa Cruz Biotechnology). Secondary antibodies were
also washed in TBS-T (36, 10 min). Bands were detected using
enhanced chemiluminescence (ECL) pico substrate (Thermo
Scientific) for all proteins except for plasma and lung pancreatic
trypsin and brain MMP-9, which were detected using the femto
substrate (Thermo Scientific). Bands were quantified in ImageJ by
Protease Activity in Hemorrhagic Shock
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RU based on the type of ECL detection utilized.
Statistical Analysis
Results are presented as mean 6 standard deviation (n=5 or 6
rats per group). We used paired t-tests or Mann-Whitney tests to
compare plasma and peritoneal fluid values before versus after
hemorrhagic shock (in individual animals) and unpaired t-tests to
compare HS+SAL versus HS+ANGD groups. Unpaired t-tests or
Mann-Whitney tests were used to compare tissue samples of the
No-HS group with HS+SAL or HS+ANGD shock groups or when
insufficient Pre-HS plasma remained to perform a paired assay.
P,0.05 was considered statistically significant.
Results
Inflammation and Intestinal Damage in Hemorrhagic
Shock
ANGD treatment reduced inflammation after shock as
measured by MPO activity (i.e. neutrophil infiltration) in brain,
heart, and lung tissues, but not significantly in liver homogenates
at two hours after reperfusion (P=0.18) (Fig. 1). ANGD treated
animals also had fewer macroscopic lesions on the intestine in the
form of visible red cell microhemorrhages into the interstitium
after hemorrhagic shock compared to saline treated animals (not
shown).
Protease Activity Detected by Small Peptide Substrates
but not Casein Substrate
When using the small peptide substrates BAPNA, SPNA, and
SAAPLPNA to assess protease activity, we observed that post-
shock plasma trypsin-, chymotrypsin-, and elastase-like activities
were all elevated after shock compared to low activity levels in pre-
shock controls (Fig. 2A). Trypsin-, chymotrypsin-, and elastase-like
activities in peritoneal fluid were also significantly elevated after
shock, though variability was enhanced in the HS+SAL group due
to individual cases with high protease activity (Fig. 2B). Overall,
trypsin and elastase activity levels were higher in the peritoneal
fluid compared to plasma, though this elastase activity could be
due in part to elastase released from neutrophils. ANGD had no
significant effect on peritoneal fluid protease activity or on plasma
protease activity other than to increase post-shock trypsin activity.
When general protease activity was measured using a casein
substrate, we saw no significant difference in plasma protease
activity two hours after HS compared to before HS (with or
without ANGD) (Fig. 3A). We saw a significant increase in
protease activity after shock in peritoneal fluid (Fig. 3B), and the
caseinolytic activity in post-shock peritoneal fluid correlated well
with MAP at 2 hours post-HS (correlation coefficient=0.86).
ANGD treatment did not significantly reduce protease activity in
peritoneal fluid compared to saline-treated animals. Interesting-
ly, PMSF significantly lowered the remaining protease activity in
nearly all cases, suggesting a portion was of serine protease
origin. There was an increase in PMSF-resistant protease activity
over the pre- to post-shock time period in the plasma of the
HS+SAL group, but not the plasma of the HS+ANGD group, in
which activity levels did not noticeably increase after shock
(Fig. 3A).
Given the tendency of post-shock plasma to clot if the small-
peptide zymography plates were not covered during digestion (see
Methods), we sought to determine whether some of the measured
increase in protease activity could be due to activation of proteases
in the clotting cascade. Supplemental heparin added to the post-
shock blood only affected chymotrypsin-like activity measured
with SPNA (from 0.17 to 0.13 normalized absorbance, P,0.04).
Similarly, there was a tendency for post-shock plasma (only) to
cause a gel to form during the casein digestion. This gel was easily
disrupted and did not form if the post-shock blood was
supplemented with heparin, which prevented coagulation. Sup-
plemental heparin gave similar results to disrupted gels (not
shown).
Figure 1. Myeloperoxidase activity. MPO activity in tissue
homogenates at 2 hours after hemorrhagic shock. N=5 rats per group.
*p,0.05 by t-test vs. HS+SAL.
doi:10.1371/journal.pone.0032672.g001
Figure 2. Plasma and peritoneal fluid serine protease activity.
Trypsin-, chymotrypsin-, and elastase-like activities in (A) plasma and (B)
peritoneal fluid expressed as equivalent activity to concentrations of
pure trypsin, chymotrypsin, and elastase. Note the difference in scales
of the ordinate. N=6 rats per group. *p,0.05, paired t-test comparing
pre vs. post HS+SAL or HS+ANGD; **p,0.05 by t-test vs. post HS+SAL;
#p,0.05, paired Mann-Whitney test comparing pre vs. post HS+SAL or
HS+ANGD.
doi:10.1371/journal.pone.0032672.g002
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Low molecular weight bands around 20 kDa (the approximate
molecular weight of pancreatic serine proteases) were also detected
in the plasma and peritoneal fluid by gelatin gel zymography
(Fig. 4A). These low molecular weight bands did not appear when
the gels were renatured and developed in buffer containing
ANGD, suggesting they could potentially be trypsin, chymotryp-
sin, and elastase. In further support of this hypothesis, renaturing
and developing in buffer containing TLCK, a trypsin-like enzyme
inhibitor, also caused a substantial reduction in the appearance of
the bands (not shown). Interestingly, ANGD treated animals had
significantly higher levels of this band in the plasma suggesting the
band corresponds primarily to trypsin activity, given our trypsin
results in Fig. 2A.
Two isoforms of pancreatic trypsin were detected in plasma by
immunoblot at 23 and 26 kDa. Variability was great for the
23 kDa band, which required femto ECL to detect. We observed a
non-significant trend for increased presence of this band after HS
(P=0.07 for HS+SAL and P=0.11 for HS+ANGD by Mann-
Whitney test). No trend was observed for the 26 kDa band in
plasma. The 26 kDa isoform of trypsin in the peritoneal fluid was
significantly increased in the HS+SAL group and to a lesser,
though still significant, extent in the HS+ANGD group (Fig. 4B
right; P=0.15 for HS+SAL vs. HS+ANGD post-shock peritoneal
fluid by Mann-Whitney test).
Lung tissue homogenates also had two distinct bands of low
molecular weight protease activity observed by gelatin zymo-
graphy that were inhibited by renaturing in ANGD (Fig. 5A).
We confirmed the proteases were at least trypsin-like in
specificity by the failure of the bands to appear as strongly
after renaturing and developing the gels in buffers containing
TLCK. The upper band was significantly elevated after shock.
We noted considerable variability in the presence of the lower
band in the HS+SAL group, but no significant differences
between the groups. Three isoforms (23, 26, and 32 kDa) of
pancreatic trypsin were detected by immunoblotting (Fig. 5B)
with the 32 kDa band likely corresponding to trypsinogen-3, the
zymogen form of trypsin-3 from the pancreas (according to the
antibody manufacturer’s datasheet). These 23 and 32 kDa
isoforms were significantly elevated after hemorrhagic shock in
the HS+SAL group. The 26 kDa isoform of pancreatic trypsin
was present in all HS+SAL animals but only detected in one
lung homogenate from the HS+ANGD group. No isoforms of
trypsin were detected in heart or liver tissues by immunoblot
(not shown).
MMP-9 Activity and Concentration
MMP-9 activity was significantly elevated after shock compared
to pre-shock levels as detected by plate zymography with the
MMP-1/9 specific substrate (Fig. 6A). Gelatin gel zymography
also revealed elevated MMP-9 bands in hemorrhagic shock that
were undetectable in pre-shock plasma and peritoneal fluid
(Fig. 6B). Immunoblot results for total protein confirmed the
presence of MMP-9 in post-HS plasma and peritoneal fluid
regardless of pre-treatment with ANGD, but little to no MMP-9
before shock (Fig. 6C). On average, MMP-9 dimer activity was
increased in the plasma of ANGD treated animals (undetectable in
HS+SAL group).
Lung, liver, and heart homogenates also had elevated MMP-9
activity levels after shock measured by gelatin gel zymography
(Fig. 7A). Immunoblot analysis revealed detectable MMP-9 in all
organs after shock, although femto chemiluminescent detection of
MMP-9 protein levels was necessary to visualize bands in the brain
homogenate (Fig. 7B).
Both pro-MMP-2 and MMP-2 were detected by gel zymo-
graphy in all samples, but there were no differences between the
groups after quantification (not shown).
Since MMP-9 can be directly activated by serine proteases, we
collected blood every 15 minutes during the first hour of ischemia
of HS+SAL animals to determine the order of appearance of
MMP-9 and serine proteases in the plasma as measured by gelatin
gel zymography and immunoblots. In all animals (N=3), bands at
the molecular weight of active MMP-9 appeared in gelatin gel
zymography and immunoblots by 15 minutes, whereas serine
protease bands in the zymography or trypsin levels measured in
the immunoblot did not distinctively appear at all during the first
hour of ischemia, suggesting MMP release and initial activation
in HS did not depend on entry of serine proteases into the
circulation.
Figure 3. Plasma and peritoneal fluid caseinolytic activity. Caseinolytic activity with and without addition of a serine protease inhibitor, 1 mM
PMSF, of (A) plasma and (B) peritoneal fluid pre/post shock with saline or ANGD pre-treatment in the intestinal lumen. Protease activity was
detectable, but low with this substrate. N=5 rats per group. *p,0.05 by paired t-test vs. without PMSF; = | p,0.05 by paired t-test comparing pre vs.
post plasma or peritoneal fluid from HS+SAL or HS+ANGD animals.
doi:10.1371/journal.pone.0032672.g003
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Following hemorrhagic shock, protease activities by trypsin-,
chymotrypsin-, elastase-like enzymes, and MMP-9 were signifi-
cantly elevated in plasma and peritoneal fluid when measured by
specific small substrates and gelatin gel zymography. However, a
general substrate, casein, detected the elevation of activity in
peritoneal fluid but not in plasma. Immunoblotting confirmed the
transport of pancreatic trypsin and the presence of increased
levels of MMP-9 activity after hemorrhagic shock in the plasma,
peritoneal fluid, and peripheral organs.
An active form of trypsin was detected in peritoneal fluid only
after shock, indicating a direct penetration of trypsin into the
peritoneal fluid from the intestinal lumen or pancreas. This
evidence suggests that after hemorrhagic shock not only the
intestinal mucosal barrier but also the entire intestinal wall in the
rat may become permeable to shock mediators and to digestive
enzymes [20]. Increased permeability could explain the presence
of inflammatory mediators in the peritoneal fluid after shock [11].
Serine proteases may also be transported by the mesenteric
lymph fluid and enter into the circulation via the thoracic duct.
The lymph fluid mixes with the blood before entering the capillary
Figure 4. Plasma and peritoneal fluid gel zymography and trypsin levels. (A) Gelatin gel zymography detection and quantification in
Relative Intensity Units (RIU; bar graph beneath) of ,20 kDa bands for plasma (right; N=6, 6, 5 rats per group) and peritoneal fluid (left; N=5 rats per
group). Bands do not form or are greatly reduced when gels are renatured with ANGD or TLCK, respectively (not shown). (B) Immunoblot detection
and quantification (bar graph beneath) of trypsin in plasma (left) and peritoneal fluid (right), revealing the 26 and 23 kDa isoforms of trypsin that are
present. +p,0.05 by Mann-Whitney test vs. Pre-HS; = | p,0.05 by t-test vs. Pre-HS; **p,0.05 by t-test HS+ANGD vs. HS+SAL; #p,0.05 pre vs. post
HS+SAL or HS+ANGD by paired Mann-Whitney test; *p,0.05 by paired t-test comparing pre vs. post HS+SAL.
doi:10.1371/journal.pone.0032672.g004
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While the increase in plasma trypsin levels after shock as measured
by immunoblotting was moderate and non-significant (femto ECL
substrate was necessary to visualize the bands by immunoblotting),
three isoforms of pancreatic trypsin were detected in the lung
homogenate and two of the three were significantly elevated in
hemorrhagic shock. Thus, it is possible that pancreatic intestinal
proteases transported through the lymphatic fluid become
entrapped in lung tissue, which is susceptible to increased vascular
permeability and protein uptake [22]. The inability to detect
pancreatic trypsin in the liver may indicate that transport of
intestinal proteases at this early stage of hemorrhagic shock
predominantly is through the lymph fluid and peritoneal fluid
rather than via the portal venous blood.
Active MMP-9 was elevated in all samples after hemorrhagic
shock, in line with reported events during ischemia-reperfusion in
organs, including non-intestinal organs [23–26]. De-novo transcrip-
tion of MMP-9 requires several hours and is less likely a major
source at the two-hour reperfusion collection in the current study,
than release of existing MMP-9. Given that endothelial cells,
neutrophils, and monocytes are all sources of MMP-9 [27,28] and
MMP-9 levels were all increased after the ischemia/reperfusion
induced by hemorrhagic shock, MMP-9 may be activated by the
ischemia associated with hemorrhagic shock rather than only by
specific events in the intestine. This hypothesis is supported by our
finding that MMP levels are increased in plasma at 15 minutes of
ischemia, while pancreatic proteases remain undetectable with
current techniques in the plasma through the first hour of
ischemia. Transport of the serine proteases may occur predom-
inately during reperfusion, when the majority of injury during
shock occurs, rather than during ischemia [29]. Since we did not
detect MMP-9 in zymogen form in the plasma during the first
hour of ischemia, it is less likely that serine proteases entering
upon reperfusion would convert appreciable amounts of zymogen
MMP-9 into its active form, though serine proteases may stimulate
further MMP release. We have shown previously that MMPs in
the ischemic intestinal wall are activated by trypsin entering from
the intestinal lumen [6], so it is also possible that additional active
MMP-9 from the intestine or pancreas enter the circulation during
reperfusion.
ANGD in the intestinal lumen reduces protease activity in an
ischemic intestine, morphological damage to the villi and systemic
inflammation [8]. Other serine protease inhibitors with similar
structure give similar protective effects when enterally adminis-
tered [30]. Our results also show that gross morphological damage
to the intestine and neutrophil infiltration in peripheral organs as
measured by organ MPO levels are decreased with ANGD
treatment. However, at 2 hours after hemorrhagic shock ANGD
had little effect on protease activities measured in compartments
distant from the intestine (plasma, as well as lung, liver, heart, and
brain homogenates). The limited effect may be due in part to the
ischemic pancreas acting as a source of plasma proteases that
would not be affected by ANGD in the lumen of the intestine. This
hypothesis is supported by the presence of a trypsinogen band in
the lung and by the fact that the 26 kDa band of trypsin, the only
band of trypsin detected in peritoneal fluid, was absent from all but
one of the lung homogenates in the HS+ANGD group, while
23 kDa and 32 kDa (trypsinogen) bands were unaffected by
intestinal ANGD treatment.
Enterally administered ANGD prevented organ neutrophil
infiltration, but did not significantly lower protease activities,
suggests that neutrophil infiltration is facilitated by the low flow
state in conjunction with shock mediators other than circulating
proteases. This hypothesis is supported by the limited efficacy in
acute shock of ANGD given i.v. as opposed to administration into
the intestinal lumen [31]. We hypothesize that there are multiple
categories of shock mediators derived from digestive enzymes or
their byproducts, which may enter into the intestinal wall and may
Figure 5. Pancreatic trypsin levels in lung tissue. (A) Two activity bands around 20 kDa were detected in lung homogenate by gel
zymography. (B) Three isoforms of trypsin were detected in lung tissue homogenate using the femto ECL substrate. The 32 kDa band corresponds to
the molecular weight of the trypsin precursor, trypsinogen, whereas the 23 and 26 kDa bands probably correspond to active forms of trypsin. N=5, 6,
6 rats per group for No-HS, HS+SAL, and HS+ANGD, respectively. #p,0.05 vs. No-HS by Mann-Whitney test; = | p,0.05 vs. No-HS by t-test.
doi:10.1371/journal.pone.0032672.g005
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intestine. These mediators may cause distant site injury after
transport from the ischemic intestine via the circulation. Besides
the digestive enzymes we focused on here, they include: 1)
bioactive peptides formed by proteolytic cleavage of extracellular
proteins in the intestine [32], 2) free fatty acids formed by
digestive lipases acting on intestinal cells and/or dietary fat in the
intestinal lumen, which may damage cells directly through a
detergent mechanism [5,33], and 3) damage associated molecular
pattern molecules (DAMPs) released from dead cells in the
intestine (e.g. after free fatty acid-induced necrosis) [32]. It is
possible that these latter mediator types may be involved in
neutrophil infiltration into organs distant from the intestine in
hemorrhagic shock.
Figure 6. MMP-9 activity and levels in plasma and peritoneal fluid. (A) Plate zymography with MMP-1/9 substrate, (B) gelatin gel
zymography, and (C) immunoblots for MMP-9 in plasma (left) and peritoneal fluid (right). MMP-9 activity was elevated by both plate and gelatin gel
zymography. There was no change in MMP-2. N=6, 5, 5 rats per group for plasma and N=6 rats per group for peritoneal fluid. Immunoblotting
quantification is reported in RU with the pico ECL substrates. = | p,0.05 vs. Pre-HS group by t-test; *p,0.05 by paired t-test comparing pre vs. post
HS+SAL or HS+ANGD.
doi:10.1371/journal.pone.0032672.g006
Protease Activity in Hemorrhagic Shock
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e32672ANGD in the lumen of the intestine also had the surprising
effect of increasing plasma trypsin-like activity, as well as
gelatinolytic activity in a band at the molecular weight of trypsin.
Plasma trypsin protein concentration, however, as determined by
immunoblot was no different after HS with saline versus with
ANGD, suggesting that the presence of ANGD may have caused
Figure 7. MMP-9 activity and levels in vital organs. (A) Gelatin gel zymography revealed increased levels of MMP-9 activity in the heart, liver,
and lung (quantifications to the right) after hemorrhagic shock. There was no change in MMP-2. (B) Immunoblot detection of MMP-9 was
upregulated in brain (bands detected with femto ECL substrate), heart, liver, and lung (bands detectable by pico ECL substrate). N=5 rats per group,
= | p,0.05 by t-test vs. No-HS.
doi:10.1371/journal.pone.0032672.g007
Protease Activity in Hemorrhagic Shock
PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e32672the trypsin that was crossing into the blood to become modified to
a more active form or activate other trypsin-like enzymes of a
similar molecular weight, rather than increasing the actual trypsin
present.
We made use of both large and small protease substrates in this
study in order to compare their efficacies in detecting protease
activity in plasma. Casein is a large globular substrate that can be
collectively cleaved by multiple protease classes (serine proteases,
MMPs, sulfhydryl, and acid proteases, etc.), making it a useful
substrate for detection of general proteolytic activity. Though it is
possible that, given a longer digestion time, plasma digested casein
may yield an improved fluorescent signal, we observed at 2 hours
reperfusion only low levels, barely above those measured by buffer
alone. Despite this, we were able to detect differences between pre-
and post-HS plasma when PMSF was used to block serine
proteases. The remaining activity could be from MMPs such as
MMP-9, which is increased after HS (Fig. 6). However, casein was
not able to detect the significant increase in overall activity in
plasma after shock that we observed using smaller, more specific
substrates.
Given that the small peptide substrates were significantly
cleaved despite levels of activity of only nanomolar concentrations
of trypsin, chymotrypsin, and elastase, whereas casein was not able
to detect differences before and after HS, casein may not be the
optimal choice for detection of protease activity in shock plasma.
Our findings support the evidence that plasma protease inhibitors
such as a2-macroglobulin, a1-antitrypsin, etc., only prevent
pancreatic proteases from hydrolyzing larger globular proteins
such as casein, but do not inhibit their activity on smaller
substrates [17]. Instead, either the actual protein of interest should
be used as a substrate, or in lieu of that, small peptide substrates
alone or in combination with the hypothesized substrate may be
better able to reveal the proteolytic potential in a given plasma
sample.
The intestine is a key organ in the etiology of shock and if the
release of mediators from the intestine is limited by ligation of the
major mesenteric lymph vessels, both lung injury and mortality are
reduced [12]. Several intestine-derived shock mediators have been
proposed, but because of the presence of plasma protease
inhibitors, digestive enzymes have mostly been discounted as
potential shock mediators distant from the intestine itself.
However, active proteases are capable of degrading surface
receptors such as the insulin receptor or activating receptors such
as the protease-activated receptors [13,34]. Furthermore, MMP-9
cleaves vascular endothelial cadherin, which is important to
maintain endothelial permeability, and is disrupted during shock
[35,36]. Cytokines pro-IL-1b and pro-TNFa are processed to their
active form by MMP-9 and are involved in vascular inflammation
during shock [37–40]. Though early neutrophil infiltration into
organs distant from the intestine may not be affected by plasma,
peritoneal, and organ protease activities, it is likely that later events
in shock, such as insulin resistance, may be linked to the action of
proteases. Thus circulating proteases may represent a distinct
damage mechanism. Organ failure in shock may be the result of
the synergy of multiple damage mechanisms.
We have shown here that both serine and MMP proteolytic
activity is increased early (2 hr ischemia/2 hr reperfusion) after
shock in plasma, peritoneal fluid, and organs distant from the
intestine, especially the lung, which is particularly vulnerable to
damage during shock. The increase in protease presence and
activities may contribute to the lethal progression of shock and
may be a target for therapeutics.
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